Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development — Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. KOS-953 is Kosan’s proprietary formulation of 17-AAG, a geldanamycin analog. The agent is currently in Phase I and II clinical trials, primarily for multiple myeloma and HER2-positive breast ( www.kosan.com )
Kosan Biosciences Incorporated
3832 Bay Center Place
Hayward, California 94545
USA
Tel: (510) 732-8400
Fax: (510) 732-8401